The effect of empagliflozin on the development of chronic heart failure after myocardial infarction according to a 12-month prospective study

The effect of empagliflozin on the development of chronic heart failure after myocardial infarction according to a 12-month prospective study

BACKGROUND: Although the positive cardiovascular effect of empagliflozin has been established, its influence on the formation of heart failure (HF) in patients with type 2 diabetes mellitus (T2D) after myocardial infarction (MI) remains unknown. AIM: To study the effect of empagliflozin on the forma...

Full description

Bibliographic Details
Main Authors:	Alexey A. Nekrasov, Elena S. Timoschenko, Leonid G. Strongin, Tatyana A. Nekrasova, Anastasiya A. Baranova, Svetlana N. Botova, Michail V. Timoschenko, Mariya A. Yaroslavtseva
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2019-10-01
Series:	Сахарный диабет
Subjects:	empagliflozin myocardial infarction the formation of chronic heart failure
Online Access:	https://www.dia-endojournals.ru/jour/article/view/10099

Similar Items

Novel cardioprotective mechanism for Empagliflozin in nondiabetic myocardial infarction with acute hyperglycemia
by: Ruhua Deng, et al.
Published: (2022-10-01)

Identification of Key Immune-Related Genes in the Treatment of Heart Failure After Myocardial Infarction with Empagliflozin Based on RNA-Seq
by: Zhang P, et al.
Published: (2023-10-01)

Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects
by: Ioanna Andreadou, et al.
Published: (2017-12-01)

Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a
by: Jana Goerg, et al.
Published: (2021-05-01)

Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial
by: Martin Benedikt, et al.
Published: (2023-07-01)

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
by: A. V. Simanenkova, et al.
Published: (2021-07-01)

Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia
by: Elena Fortin, et al.
Published: (2023-08-01)

Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice
by: Genlong Xue, et al.
Published: (2022-10-01)

Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: a study protocol for a randomized, double-blinded, three-arm parallel-group, controlled trial
by: Sajad Khiali, et al.
Published: (2023-10-01)

Green quantitative methods for linagliptin and empagliflozin in dosage forms
by: Fraihat Safwan M.
Published: (2024-04-01)

Protective effects of empagliflozin on methotrexate induced hepatotoxicity in rats
by: Elham Kalantari, et al.
Published: (2024-01-01)

Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial
by: Faisal Aziz, et al.
Published: (2023-07-01)

Empagliflozin: a potential anticancer drug
by: Wenwen Wu, et al.
Published: (2023-07-01)

Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice
by: Yang Y, et al.
Published: (2024-03-01)

Effect of high-fat diet and empagliflozin on cardiac proteins in mice
by: Xiaoyu Pan, et al.
Published: (2022-10-01)

Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells
by: Sha Chen, et al.
Published: (2023-07-01)

Empagliflozin in type 1 diabetes
by: Mathieu C, et al.
Published: (2019-08-01)

Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
by: Xiaoyi Chen, et al.
Published: (2023-03-01)

Greenness Assessment of Chromatographic Methods Used for Analysis of Empagliflozin: A Comparative Study
by: Eman Y. Santali, et al.
Published: (2022-10-01)

Metformin, Empagliflozin, and Their Combination Modulate Ex-Vivo Macrophage Inflammatory Gene Expression
by: Adittya Arefin, et al.
Published: (2023-03-01)

A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES
by: M. V. Amosova, et al.
Published: (2017-12-01)

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice
by: Niu S, et al.
Published: (2023-08-01)

Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin
by: Haroon Aziz, et al.
Published: (2023-06-01)

Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes
by: Ingrid Reppo, et al.
Published: (2023-03-01)

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice [Corrigendum]
by: Niu S, et al.
Published: (2023-09-01)

[Budget impact analysis of empagliflozin for the treatment of type 2 diabetes in Italy]
by: Sergio Iannazzo, et al.
Published: (2016-03-01)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
by: Asima Khan, et al.
Published: (2022-08-01)

Empagliflozin alone and in combination with metformin ameliorate diabetes type 2-oxidative stress
by: Zena S. Madhag, et al.
Published: (2023-12-01)

Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
by: Marvin Heimke, et al.
Published: (2022-10-01)

Comparative study of three brands of antidiabetic drug, empagliflozin available in Karachi, Pakistan
by: Khadija Aslam, et al.
Published: (2023-04-01)

Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure
by: Michael Gotzmann, et al.
Published: (2023-07-01)

Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin
by: Shih-Jie Jhuo, et al.
Published: (2021-06-01)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
by: Hilmi Alnsasra, et al.
Published: (2023-08-01)

Effect of empagliflozin on cytoskeletal repair in the hippocampus of obese mice
by: Xiaoyi Chen, et al.
Published: (2022-11-01)

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved
by: Andrew J.S. Coats, et al.
Published: (2024-02-01)

Empagliflozin: a new strategy for nephroprotection in diabetes
by: Anton Ivanovich Korbut, et al.
Published: (2017-05-01)

Association between Empagliflozin Use and Electrocardiographic Changes
by: Daniel Antwi-Amoabeng, et al.
Published: (2022-07-01)

Attenuation of Adverse Postinfarction Left Ventricular Remodeling with Empagliflozin Enhances Mitochondria-Linked Cellular Energetics and Mitochondrial Biogenesis
by: Yang Song, et al.
Published: (2021-12-01)

Glycemia in patients with type 2 diabetes during inpatient treatment for acute myocardial infarction: impact on prognosis
by: M. A. Korotina, et al.
Published: (2021-04-01)

Biochemical and histopathological evidence for beneficial effects of Empagliflozin pretreatment on acetic acid-induced colitis in rats
by: Fereshteh Nazari-Khanamiri, et al.
Published: (2023-09-01)